BIOGEN INC. (BIIB) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31..
Quick ratio
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 3.00B USD | Liabilities, Current |
| Cash and equivalents | (m) | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 900.00M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 1.95B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-03-31 | (m) | $3.00B | (m) | $900.00M | (m) | $1.95B | (m) |
| 2025-12-31 | (m) | $3.35B | (m) | $807.20M | $1.34B | $2.17B | (m) |
| 2025-09-30 | (m) | $3.29B | (m) | $97.60M | (m) | $2.21B | (m) |
| 2025-06-30 | (m) | $3.18B | (m) | (m) | (m) | $2.27B | (m) |
| 2025-03-31 | (m) | $5.30B | (m) | (m) | (m) | $2.27B | (m) |
| 2024-12-31 | (m) | $5.53B | (m) | (m) | $1.40B | $2.46B | (m) |
| 2024-09-30 | (m) | $5.42B | (m) | (m) | (m) | $2.47B | (m) |
| 2024-06-30 | (m) | $3.11B | (m) | (m) | (m) | $2.51B | (m) |
| 2024-03-31 | (m) | $3.22B | (m) | (m) | (m) | $2.52B | (m) |
| 2023-12-31 | (m) | $3.43B | (m) | $0.00 | $1.66B | $2.53B | (m) |
| 2023-09-30 | (m) | $5.02B | (m) | $0.00 | (m) | $2.98B | (m) |
| 2023-06-30 | (m) | $3.19B | (m) | $3.46B | (m) | $1.33B | (m) |
| 2023-03-31 | (m) | $3.01B | (m) | $2.14B | $1.63B | $1.28B | (m) |
| 2022-12-31 | (m) | $3.27B | (m) | $1.47B | $1.71B | $1.34B | (m) |
| 2022-09-30 | (m) | $3.93B | (m) | $1.24B | $1.57B | $1.38B | (m) |
| 2022-06-30 | (m) | $5.02B | (m) | $2.15B | $1.57B | $1.29B | (m) |
| 2022-03-31 | (m) | $3.95B | (m) | $2.00B | $1.63B | $1.22B | (m) |
| 2021-12-31 | (m) | $4.30B | (m) | $1.54B | $1.55B | $1.35B | (m) |
| 2021-09-30 | (m) | $4.21B | (m) | $1.41B | $1.72B | $1.35B | (m) |
| 2021-06-30 | (m) | $3.35B | (m) | $1.31B | $1.69B | $1.25B | (m) |
| 2021-03-31 | (m) | $3.17B | (m) | $1.32B | $1.85B | $1.17B | (m) |
| 2020-12-31 | (m) | $3.74B | (m) | $1.28B | $1.91B | $1.07B | (m) |
| 2020-09-30 | (m) | $3.80B | (m) | $1.35B | $2.02B | $1.03B | (m) |
| 2020-06-30 | (m) | $3.45B | (m) | $1.94B | $2.13B | $952.70M | (m) |
| 2020-03-31 | (m) | $4.64B | (m) | $1.27B | $2.09B | $858.80M | (m) |
| 2019-12-31 | $6.36B | $4.86B | $2.91B | $1.56B | $1.88B | $804.20M | 1.31× |
| 2019-09-30 | $6.37B | $4.43B | $2.34B | $2.09B | $1.93B | $751.80M | 1.44× |
| 2019-06-30 | $4.91B | $3.21B | $1.72B | $1.23B | $1.96B | $776.70M | 1.53× |
| 2019-03-31 | $6.00B | $3.15B | $2.24B | $1.67B | $2.09B | $770.20M | 1.90× |
| 2018-12-31 | $5.50B | $3.30B | $1.22B | $2.31B | $1.96B | $929.90M | 1.67× |
| 2018-09-30 | $6.45B | $3.17B | $2.39B | $2.04B | $2.02B | $916.60M | 2.03× |
| 2018-06-30 | $5.18B | $3.15B | $1.25B | $1.97B | $1.95B | $931.70M | 1.64× |
| 2018-03-31 | $7.86B | $3.15B | $4.11B | $1.81B | $1.94B | $890.80M | 2.49× |
| 2017-12-31 | $5.48B | $3.37B | $1.57B | $2.12B | $1.79B | $902.70M | 1.63× |
| 2017-09-30 | $5.08B | $3.45B | $1.55B | $1.96B | $1.57B | $1.01B | 1.47× |
| 2017-06-30 | $4.52B | $3.38B | $1.17B | $1.72B | $1.63B | $936.50M | 1.34× |
| 2017-03-31 | $4.38B | $2.99B | $924.00M | $1.96B | $1.50B | $921.60M | 1.46× |
| 2016-12-31 | $6.34B | $3.42B | $2.33B | $2.57B | $1.44B | $1.00B | 1.85× |
| 2016-09-30 | $5.78B | $2.50B | $2.08B | $2.23B | $1.47B | $1.01B | 2.31× |
| 2016-06-30 | $5.09B | $2.52B | $1.36B | $2.43B | $1.29B | $996.40M | 2.02× |
| 2016-03-31 | $4.98B | $2.78B | $1.13B | $2.45B | $1.40B | $964.60M | 1.79× |
| 2015-12-31 | $4.66B | $2.58B | $1.31B | $2.12B | $1.23B | $893.40M | 1.81× |
| 2015-09-30 | $7.17B | $2.63B | $4.09B | $1.75B | $1.33B | $918.92M | 2.72× |
| 2015-06-30 | $3.68B | $2.56B | $1.28B | $1.09B | $1.31B | $865.74M | 1.44× |
| 2015-03-31 | $3.54B | $1.95B | $1.48B | $673.95M | $1.39B | $825.35M | 1.82× |
| 2014-12-31 | $3.14B | $2.22B | $1.20B | $640.46M | $1.29B | $804.02M | 1.41× |
| 2014-09-30 | $2.95B | $1.94B | $1.19B | $675.07M | $1.09B | $753.06M | 1.52× |
| 2014-06-30 | $2.58B | $1.92B | $863.20M | $709.87M | $1.00B | $715.93M | 1.34× |
| 2014-03-31 | $2.28B | $1.59B | $828.60M | $431.61M | $1.02B | $672.75M | 1.43× |
| 2013-12-31 | $2.05B | $1.76B | $602.56M | $620.17M | $824.41M | $659.00M | 1.16× |
| 2013-09-30 | $1.56B | $1.52B | $427.81M | $240.88M | $891.40M | $614.48M | 1.03× |
| 2013-06-30 | $1.53B | $1.30B | $392.51M | $275.16M | $861.46M | $570.39M | 1.17× |
| 2013-03-31 | $1.42B | $1.28B | $663.30M | $0.00 | $753.61M | $506.56M | 1.11× |
| 2012-12-31 | $2.39B | $1.66B | $570.72M | $1.13B | $686.85M | $447.37M | 1.44× |
| 2012-09-30 | $2.27B | $1.52B | $451.72M | $1.15B | $661.52M | $392.94M | 1.49× |
| 2012-06-30 | $2.09B | $1.43B | $456.81M | $949.24M | $683.84M | $362.94M | 1.46× |
| 2012-03-31 | $1.96B | $1.34B | $298.14M | $978.47M | $684.24M | $337.62M | 1.47× |
| 2011-12-31 | $2.28B | $912.89M | $514.54M | $1.18B | $584.60M | $326.84M | 2.49× |
| 2011-09-30 | $2.10B | $885.35M | $575.14M | $944.38M | $581.05M | $310.93M | 2.37× |
| 2011-06-30 | $1.99B | $954.33M | $697.53M | $629.22M | $666.96M | $308.25M | 2.09× |
| 2011-03-31 | $1.92B | $978.85M | $790.67M | $437.87M | $687.61M | (m) | 1.96× |
| 2010-12-31 | $1.81B | $1.05B | $759.60M | $448.15M | $605.33M | (m) | 1.73× |
| 2010-09-30 | $1.44B | $824.48M | $626.76M | $197.84M | $616.70M | (m) | 1.75× |
| 2010-06-30 | $1.52B | $755.66M | $720.96M | $248.71M | $548.89M | $267.88M | 2.01× |
| 2010-03-31 | $1.71B | $682.33M | $639.56M | $513.12M | $560.78M | $280.04M | 2.51× |
| 2009-12-31 | $1.81B | $714.94M | $581.89M | $681.84M | $551.21M | $293.95M | 2.54× |
| 2009-09-30 | $1.96B | $721.37M | $585.79M | $821.89M | $551.00M | $278.69M | 2.72× |
| 2009-06-30 | $2.13B | $803.93M | $786.80M | $836.27M | $511.29M | $268.53M | 2.65× |
| 2009-03-31 | (m) | (m) | $764.10M | (m) | (m) | (m) | (m) |
| 2008-12-31 | $1.79B | $923.22M | $622.38M | $719.59M | $446.67M | $263.60M | 1.94× |
| 2008-09-30 | (m) | (m) | $1.01B | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $466.49M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $659.66M | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $661.38M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |